We are live on ! Find out more
SONN

Sonnet BioTherapeutics
SONN

Delisted

SONN was delisted on the 2nd of December, 2025.

Back to rankings

Fund managers haven’t disclosed any holdings of SONN yet.

SONN Hedge Fund Activity: Q1 2026 in Review

0 of the 8,131 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q1 2026, worth a combined $0 — down 100% from $170K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of SONN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Formidable Asset Management, exiting entirely with an estimated $170K sold.

  • 0 institutional investors held Sonnet BioTherapeutics (SONN) as of Q1 2026, down from 1 in Q4 2025.
  • Funds reported $0 of Sonnet BioTherapeutics stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Sonnet BioTherapeutics positions in Q1 2026 and 1 closed out, a net change of -1 holder.
  • The largest Sonnet BioTherapeutics seller in Q1 2026 was Formidable Asset Management, an estimated $170K sold.

Based on aggregated 13F filings for Q1 2026.